�鶹��ýӰ��

Meeting Coverage >

AHA

AHA Dedicates $20 Million to Youth Vaping Research

Association and partners aim to "hold e-cigarette companies publicly accountable for their lies"

Vaping Worse for Heart Than Cigarettes?

It's not just lung injury e-cigarette users should worry about, study says

AHA: Neighborhood Violence Takes Toll on Heart

Studies connect steady diet of violence to early heart disease

AHA: Stem Cells No Help in LVAD Patients

Mesenchymal precursor cells didn't boost wean rates from heart assist devices

AHA: Closing Dialysis Fistula Improves Heart Function

Kidney transplant patients may benefit from reversing arteriovenous connection

AHA: CABG Still Better for Multivessel Disease in Diabetes

FREEDOM trial extension suggests lower long-term mortality vs stents

National Exercise Guidelines Now Say 'Just Move'

HHS recs say to sit less, move more to improve health outcomes

AHA: Rivaroxaban May Cut Thromboembolic Risk in HF Patients

Post hoc analysis of COMMANDER HF trial suggestive of benefit

AHA: Novel Agent Promising for Lowering Lp(a) Levels

Treatment with AKCEA-APO(a)-LRx better than placebo at multiple doses

AHA: DCM Recovery Often Doesn't Mean Cure

Stopping meds led to relapse of dilated cardiomyopathy for many in TRED-HF trial

AHA: Zetia May Cut CV Events in Japanese Seniors

Results from EWTOPIA75 trial not enough to change practice, experts says

AHA: In-hospital Entresto Safe, Beneficial in HFrEF

PIONEER-HF shows improved biomarkers and possibly outcomes too

AHA: Yoga-Based Cardiac Rehab Shows Promise in MI Patients

Patients in Indian study saw QoL improvements, return to pre-infarct daily activities

AHA: Fish Oil, Vitamin D Not VITAL to Heart Health

VITAL trial also showed no benefits for cancer incidence with both supplements

AHA: Mixed Results with Dapagliflozin in T2D Patients

SGLT2 inhibitor didn't change MACE rate, but did result in other positive CV outcomes

AHA: Targeting Inflammation With Methotrexate Flops for CV Prevention

CIRT trial disappoints after CANTOS' win for the inflammatory hypothesis

AHA: Prescription Fish Oil Wins for CV Prevention

Positive findings for Vascepa in REDUCE-IT trial

AHA: Revised Lipid Guide Boosts PCSK9s, Coronary Calcium Scans

New recommendations aim to cut statins in low-risk primary prevention

AHA: Lipid Guidelines to Headline Meeting

Exercise, fish oil, Entresto in acute HF, and an anti-inflammatory also in the spotlight

AHA: Late Meals Linked to HTN, Prediabetes

Risks seen in study of Hispanic and Latino Americans

AHA: ORBITA Debate Continues

Gersh, Mehran, Block, Yeh, Chazal, Bairey Merz, Brown, Eagle weigh in

'Safer' Cigarettes Still Prove Harmful to Blood Vessels

Heat-not-burn product impacts endothelial function in animal model

AHA: Everybody Now Is a Clinical Investigator, Says Califf

Time to revolutionize clinical data gathering, ex-FDA Commissioner urges

AHA: BP Measurement in SPRINT Was All Over the Place

Did varying presence of staff during BP readings ruin a huge study?

AHA: Follow Same HTN Cutoff for Adults and Teens

But adult and pediatric hypertension guidelines differ in other respects

AHA: Evolocumab's Absolute Benefit Greater in PAD Patients

Symptomatic PAD yields bigger bang for PCSK9 big bucks

Heart Attack Fells AHA President During Annual Meeting

The AHA reports that he received a stent and is doing well

AHA: 130/80 mm Hg Is New National BP Target

Multisociety guidelines released accounting for SPRINT data

AHA: Brief NOAC Interruption Safer Than Warfarin in Afib Ablation

Fewer major bleeds than with uninterrupted warfarin in Japanese trial

AHA: CANTOS Substudy Supports Major Role of Inflammation

Large reductions in hsCRP appeared to foretell improved outcomes

AHA: For CIED Surgery, NOAC Administration Up to Clinician

Continued or interrupted therapy carried same risk of clinically significant hematoma development

AHA: Restrictive Blood Transfusion OK for Select Patients

Stricter approach deemed noninferior to liberal strategy in cardiac surgery

AHA: ACA Program Offers Mixed Results for HF Readmits

HRRP tied to less readmissions, but seems to up mortality

Sex: Odds Are It Won't Kill You

But when it is fatal, the victim is likely to be male

Trial: No Benefit for High-Dose Diuretic in Acute HF

But phase II results might not be the final word

AHA: Mixed Results For ApoA-1 Therapies

But it's still not time to write the obituary for all HDL therapies

AHA: No Pump Thrombosis With Next-Gen LVAD?

Better outcomes in HeartMate 3 trial hinged on fewer malfunctions

AHA: Lower Better for Plaque Regression with PCSK9 Drugs

No diminishing returns at very low LDL levels in GLAGOV trial

AHA: Real World TAVR Is All About Patient Selection

Intermediate risk is a moving target

Statin 'Census' Shows Major Disparities

Women, minorities treated at significantly lower rates

3